PMID- 17425753
OWN - NLM
STAT- MEDLINE
DCOM- 20070529
LR  - 20181217
IS  - 0902-0063 (Print)
IS  - 0902-0063 (Linking)
VI  - 21
IP  - 2
DP  - 2007 Mar-Apr
TI  - Nateglinide improves postprandial hyperglycemia and insulin secretion in renal 
      transplant recipients.
PG  - 246-51
AB  - BACKGROUND: Postprandial hyperglycemia (PPHG) frequently occurs among renal 
      transplant recipients (RTR). Reduced early insulin response (EIR) after a meal 
      leads to impaired suppression of endogenous glucose production and subsequently 
      PPHG, which is a risk factor for cardiovascular disease. Nateglinide is a rapid 
      acting insulin secretagogue inducing an EIR after a meal. Our main objective was 
      to investigate the safety and effect of nateglinide treatment on postprandial 
      plasma glucose excursions and insulin secretion in RTR with PPHG. PATIENTS AND 
      METHODS: A total of 14 Caucasian RTR with new-onset diabetes mellitus (NODM; n = 
      6) or impaired glucose tolerance (IGT; n = 8) were included. The insulin response 
      and glucose excursions were measured for 240 min after a standardized liquid meal 
      at baseline and after two-wk treatment with nateglinide. RESULTS: Treatment with 
      nateglinide was followed by a significant decrease in mean two-h plasma glucose 
      from 10.5 mmol/L (3.1) to 7.6 mmol/L (2.1; p < 0.001) and a decline in total 
      postprandial area under the curve (AUC) of glucose concentration (p < 0.001). 
      Both estimated EIR and the late insulin response increased significantly (p = 
      0.008 and p = 0.003, respectively). No serious adverse event was observed during 
      the study period. CONCLUSIONS: Treating RTR with nateglinide for two-wk 
      significantly improved PPHG, increased the insulin response following a 
      standardized meal and was well tolerated.
FAU - Voytovich, Monica Hagen
AU  - Voytovich MH
AD  - Section of Nephrology, Department of Medicine, Rikshospitalet Radiumhospitalet 
      HF, University of Oslo, Oslo, Norway. monicagh@studmed.uio.no
FAU - Haukereid, Cecilie
AU  - Haukereid C
FAU - Hjelmesaeth, Joran
AU  - Hjelmesaeth J
FAU - Hartmann, Anders
AU  - Hartmann A
FAU - Lovik, Astrid
AU  - Lovik A
FAU - Jenssen, Trond
AU  - Jenssen T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Denmark
TA  - Clin Transplant
JT  - Clinical transplantation
JID - 8710240
RN  - 0 (Blood Glucose)
RN  - 0 (Cyclohexanes)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 41X3PWK4O2 (Nateglinide)
RN  - 47E5O17Y3R (Phenylalanine)
SB  - IM
MH  - Aged
MH  - Blood Glucose/*drug effects
MH  - Cyclohexanes/administration & dosage/*pharmacology/therapeutic use
MH  - Female
MH  - Humans
MH  - Hyperglycemia/*prevention & control
MH  - Hypoglycemic Agents/administration & dosage/*pharmacology/therapeutic use
MH  - Insulin/*metabolism
MH  - Insulin Secretion
MH  - Kidney Transplantation/*physiology
MH  - Male
MH  - Middle Aged
MH  - Nateglinide
MH  - Phenylalanine/administration & dosage/*analogs & 
      derivatives/pharmacology/therapeutic use
MH  - Postprandial Period/*drug effects/physiology
EDAT- 2007/04/12 09:00
MHDA- 2007/05/30 09:00
CRDT- 2007/04/12 09:00
PHST- 2007/04/12 09:00 [pubmed]
PHST- 2007/05/30 09:00 [medline]
PHST- 2007/04/12 09:00 [entrez]
AID - CTR634 [pii]
AID - 10.1111/j.1399-0012.2006.00634.x [doi]
PST - ppublish
SO  - Clin Transplant. 2007 Mar-Apr;21(2):246-51. doi: 
      10.1111/j.1399-0012.2006.00634.x.